INT200669

Context Info Confidence 0.42 First Reported 2006 Last Reported 2009 Negated 0 Speculated 0 Reported most in Body Documents 2 Total Number 2 Disease Relevance 0.94 Pain Relevance 0.72

nucleoplasm (AKT2) transport (AKT2) mitochondrion (AKT2) carbohydrate metabolic process (AKT2) cytoplasm (AKT2) cytosol (AKT2)

Anatomy Link Frequency paw 1 AKT2 (Homo sapiens)

Pain Link Frequency Relevance Heat withdrawal 8 100.00 intrathecal 14 98.72 allodynia 2 94.88 Brush evoked pain 20 88.60 Peripheral nerve injury 5 65.20 Stimulus evoked pain 2 54.04 Neuropathic pain 15 52.04 Dorsal horn neuron 8 50.68 Thermal hyperalgesia 1 46.56 Spinal cord 11 17.92

Disease Link Frequency Relevance Heat Neuropathic Pain 37 94.88 Death 25 78.48 Apoptosis 41 74.28 Cervical Cancer 5 66.88 Nervous System Injury 17 65.20 Hypersensitivity 2 54.04 Pain 9 53.36 Cancer 26 50.00 Hyperalgesia 1 46.56 Repression 2 5.00

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

Consistent with the previous results in mice [24], intrathecal pretreatment with AG17 (100 nmol) significantly attenuated the decrease in the paw withdrawal threshold 7 days after PDGF administration (PDGF-BB + vehicle group, 1.71 ± 0.41, n = 4; PDGF-BB + AG17 group, 9.43 ± 1.13, n = 4; P < 0.001).

Negative_regulation (decrease) of -BB in paw associated with withdrawal and intrathecal

1) Confidence 0.42 Published 2009 Journal Mol Pain Section Body Doc Link PMC2690582 Disease Relevance 0.54 Pain Relevance 0.72

As shown in Fig. 1B, following 16 hours of butyrate treatment, the levels of Akt1 and Akt2 mRNA were reduced by about 70% and 50% respectively as compared to untreated control cells.

Negative_regulation (reduced) of Akt2 mRNA

2) Confidence 0.38 Published 2006 Journal Mol Cancer Section Body Doc Link PMC1762018 Disease Relevance 0.40 Pain Relevance 0

General Comments

This test has worked.